secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2022-11-23T23:59:59+00:00
Accession:  0000950170-22-025666
Event type: regulatory
Sentiment:  negative
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics receives Nasdaq non-compliance letter for audit committee shortage; cure period to Oct 2023
--------------------------------------------------------------------------------

- Received Nasdaq letter Nov 18, 2022: audit committee has 2 independent directors instead of required 3.
- Cure period expires at earlier of next annual meeting or Oct 31, 2023; if meeting before May 1, 2023, then May 1, 2023.
- Company plans to appoint an additional independent director to regain compliance.
- No immediate impact on listing or trading of FLGT common stock on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022025666/0000950170-22-025666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017022025666/flgt-20221118.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-025666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer